Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BOLD vs. SLRN, DMAC, AMRN, GOSS, MGNX, OGI, PRQR, NLTX, PROC, and ZNTLShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Acelyrin (SLRN), DiaMedica Therapeutics (DMAC), Amarin (AMRN), Gossamer Bio (GOSS), MacroGenics (MGNX), Organigram (OGI), ProQR Therapeutics (PRQR), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. Acelyrin DiaMedica Therapeutics Amarin Gossamer Bio MacroGenics Organigram ProQR Therapeutics Neoleukin Therapeutics Procaps Group Zentalis Pharmaceuticals Acelyrin (NASDAQ:SLRN) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings. Do analysts prefer SLRN or BOLD? Acelyrin currently has a consensus target price of $9.60, indicating a potential upside of 382.41%. Audentes Therapeutics has a consensus target price of $23.00, indicating a potential upside of 799.49%. Given Audentes Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Audentes Therapeutics is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Audentes Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals have more ownership in SLRN or BOLD? 87.3% of Acelyrin shares are held by institutional investors. 13.6% of Acelyrin shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer SLRN or BOLD? In the previous week, Acelyrin had 1 more articles in the media than Audentes Therapeutics. MarketBeat recorded 1 mentions for Acelyrin and 0 mentions for Audentes Therapeutics. Acelyrin's average media sentiment score of 1.66 beat Audentes Therapeutics' score of 0.00 indicating that Acelyrin is being referred to more favorably in the media. Company Overall Sentiment Acelyrin Very Positive Audentes Therapeutics Neutral Which has higher valuation & earnings, SLRN or BOLD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcelyrinN/AN/A-$381.64M-$2.46-0.81Audentes TherapeuticsN/AN/A-$49.43MN/AN/A Is SLRN or BOLD more profitable? Acelyrin's return on equity of -44.12% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AcelyrinN/A -44.12% -39.02% Audentes Therapeutics N/A -321.10%-40.02% Does the MarketBeat Community favor SLRN or BOLD? Audentes Therapeutics received 454 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 69.12% of users gave Audentes Therapeutics an outperform vote while only 55.17% of users gave Acelyrin an outperform vote. CompanyUnderperformOutperformAcelyrinOutperform Votes1655.17% Underperform Votes1344.83% Audentes TherapeuticsOutperform Votes47069.12% Underperform Votes21030.88% SummaryAcelyrin beats Audentes Therapeutics on 6 of the 11 factors compared between the two stocks. Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.42M$6.56B$5.38B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A9.3686.9417.29Price / SalesN/A329.751,267.38137.12Price / CashN/A22.6336.6032.88Price / BookN/A5.084.974.69Net Income-$49.43M$154.90M$117.89M$224.57M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics2.0949 of 5 stars$2.56+11.2%$23.00+799.5%N/A$56.42MN/A0.00207Gap UpSLRNAcelyrin2.9873 of 5 stars$2.15+4.4%$9.60+346.5%-66.3%$215.70MN/A-0.87135DMACDiaMedica Therapeutics0.7208 of 5 stars$4.96-5.9%$7.00+41.1%+105.7%$212.10MN/A-8.8620AMRNAmarin0.0646 of 5 stars$0.51-6.7%N/A-45.8%$211.37M$241.02M-5.72360GOSSGossamer Bio4.5127 of 5 stars$0.92-5.1%$9.20+896.9%+6.0%$209.13M$105.32M-2.88180Positive NewsMGNXMacroGenics3.6685 of 5 stars$3.17-0.3%$7.63+140.5%-75.0%$198.96M$139.77M-2.01430OGIOrganigram0.6066 of 5 stars$1.57flatN/A-17.2%$198.07M$159.84M-3.74860PRQRProQR Therapeutics2.775 of 5 stars$2.27-6.2%$8.83+289.1%+7.2%$185.41M$17.88M-7.09180NLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-44.8%$184.01MN/A-6.3090Gap DownHigh Trading VolumePROCProcaps GroupN/A$1.63+1.9%N/A-62.7%$183.90M$414.10M3.135,500Positive NewsGap UpZNTLZentalis Pharmaceuticals2.8956 of 5 stars$2.56-6.9%$10.00+290.6%-82.5%$182.44M$40.56M-1.03160 Related Companies and Tools Related Companies Acelyrin Competitors DiaMedica Therapeutics Competitors Amarin Competitors Gossamer Bio Competitors MacroGenics Competitors Organigram Competitors ProQR Therapeutics Competitors Neoleukin Therapeutics Competitors Procaps Group Competitors Zentalis Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLD) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
